Kane Biotech Inc., Winnipeg, MB

Kane Biotech Inc. is dedicated to the research and development of products to prevent and disperse microbial biofilms. The Company was formed in 2001 and is developing products for the prevention and dispersal of biofilms focused on the genetic mechanisms of biofilm formation, and originally based upon the discovery of over 60 novel anti-biofilm targets. Kane Biotech Inc. uses a patent protected technology based on molecular mechanisms of biofilm formation and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that this technology has potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications. Biofilms are estimated to be responsible for 80% of all human infections and cost industry, cities and hospitals in excess of $500 billion each year. Kane Biotech has a growing pipeline of products based on the Company's ability to screen for factors affecting biofilm formation and has resulted in the development of candidate products based on the demand for safe and effective anti-biofilm compounds. Vision To become a global leader in creating innovative technology to breakdown and disperse biofilms and to develop unique products that have a positive impact on human health. Mission To discover and commercialize compelling technology that will prevent and cure infections in healthcare and animal agriculture and offer solutions to biofilm related problems in industrial applications.